Related Experiment Video
Updated: Jan 10, 2026

07:31
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
7.5K
A Self-Explainable Dynamic Risk Monitoring Framework for Predicting Alzheimer's Disease and Related Dementias
Xiaoyang Ruan1, Shuyu Lu1, Sunyang Fu1
1Department of Health Data Science and AI, McWilliams School of Biomedical Informatics, UT Health Houston, Houston, United States.
Medrxiv : the Preprint Server for Health Sciences
|November 24, 2025
Summary
Early Alzheimer's Disease and Related Dementias (ADRD) prediction is possible using Electronic Health Records (EHR). GRU-D-RETAIN offers interpretable risk monitoring up to 10 years before diagnosis, crucial for timely intervention.
Area of Science:
- Biomedical Informatics
- Machine Learning in Healthcare
- Neuroscience
Background:
- Alzheimer's Disease and Related Dementias (ADRD) pose a significant global health challenge, often progressing silently for over a decade.
- Early detection is critical as ADRD becomes largely irreversible upon symptom manifestation.
- While neuroimaging aids prediction, its limited accessibility necessitates scalable alternatives like Electronic Health Records (EHR).
Purpose of the Study:
- To develop a temporal deep learning model for early ADRD prediction using EHR data.
- To address challenges of irregular data, sparsity, and interpretability in EHR-based prediction.
- To enable real-time, interpretable risk monitoring for ADRD.
Main Methods:
- Utilized EHR data from 15,172 ADRD cases and 145,443 controls from the UT Physician EHR system.
- Developed GRU-D-RETAIN, a temporal deep learning architecture combining GRU-D imputation with RETAIN's attention mechanism.
- Trained and validated models using 6-fold cross-validation, comparing GRU-D-RETAIN against GRU-D, LSTM, Logit static, and Logit dynamic.
Main Results:
- GRU-D-RETAIN demonstrated strong performance, closely matching GRU-D, with accuracy improving as follow-up time increased.
- Models achieved AUROC of 0.7 at 8-year follow-up without data cut-offs, outperforming other methods.
- Data completeness was more critical than follow-up length for prediction accuracy; 1 year with 15% data yielded performance comparable to 7.5 years with 10% data.
Conclusions:
- EHR data can facilitate dynamic ADRD risk monitoring up to 10 years pre-diagnosis, contingent on data completeness.
- GRU-D-RETAIN provides real-time, interpretable risk assessment, aiding clinicians in identifying high-risk patients and key factors.
- The GRU-D-RETAIN framework is adaptable for other conditions requiring dynamic, interpretable risk prediction with irregular data.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Dementia
498
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
498
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772

